Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/29/2003WO2002036117A1 Medicinal compositions for concominant use as anticancer atent
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555676 Antitumor agents
04/29/2003US6555667 Hypoxia-regulated genes
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555571 3-methyl -chromane or thiochromane derivatives
04/29/2003US6555558 Oral dosage self-emulsifying formulations of pyranone protease inhibitors
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555539 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
04/29/2003US6555535 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
04/29/2003US6555533 Specific antitumor activity against breast, colon, lung, prostate cancers and melanomas
04/29/2003US6555527 Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng
04/29/2003US6555520 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and immunologicval disorders
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555368 Single-chain antibody introduced into the minor capsid proteins so that the adenoviral vector can be targeted to a particular cell type
04/29/2003US6555352 Peptide for use in human therapeutics and diagnostic compositions
04/29/2003US6555322 Connective tissue growth factor (CTGF); drug screening for agents that modulate the activity of a CTGF receptor comprising the alpha 2- macroglobulin receptor
04/29/2003CA2227513C New ellipticine derivatives, their preparation process and the pharmaceutical compositions containing them
04/29/2003CA2159098C Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
04/29/2003CA2011992C Use of human interferon-beta for stimulation of erythropoiesis
04/25/2003CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
04/24/2003WO2003034069A2 Tcmp 03 protein for use in cancer therapy
04/24/2003WO2003034067A1 Modulation of tor
04/24/2003WO2003034028A2 Methods for identifying and using modulators of estrogen related receptor gamma
04/24/2003WO2003033720A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
04/24/2003WO2003033700A1 Method for inhibiting the replication of viruses
04/24/2003WO2003033696A1 Vegf antisense compound
04/24/2003WO2003033692A2 Use of the adenoviral e2 late promoter
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033674A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity
04/24/2003WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor
04/24/2003WO2003033654A2 Direct targeting binding proteins
04/24/2003WO2003033653A2 Affinity enhancement agents
04/24/2003WO2003033529A2 Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases
04/24/2003WO2003033525A1 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
04/24/2003WO2003033523A2 Cytotoxic compounds
04/24/2003WO2003033518A1 Steroidal compounds for inhibiting steroid sulphatase
04/24/2003WO2003033517A1 Ship 1 modulators
04/24/2003WO2003033514A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
04/24/2003WO2003033511A1 Pt(iv) complex with antineoplastic activity: trans-[ptcl2(oh)2 (dimethylamine) (isopropylamine)] used as an antitumour agent
04/24/2003WO2003033507A1 Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
04/24/2003WO2003033506A1 Aminoborane acid derivative and proteasome inhibitory drug containing the same
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033501A1 Himbacine analogues as thrombin receptor antagonists
04/24/2003WO2003033499A2 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
04/24/2003WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors
04/24/2003WO2003033494A1 Benzimidazole derivative
04/24/2003WO2003033493A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
04/24/2003WO2003033491A1 Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition
04/24/2003WO2003033487A1 Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
04/24/2003WO2003033484A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033478A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
04/24/2003WO2003033472A1 Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
04/24/2003WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033455A1 Oligoamine compounds and derivatives thereof for cancer therapy
04/24/2003WO2003033030A1 Pacap compositions and methods for tumor imaging and therapy
04/24/2003WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications
04/24/2003WO2003033027A2 Dendrimers for use in targeted delivery
04/24/2003WO2003033024A1 Cell proliferation inhibitor
04/24/2003WO2003033021A1 Use of peptide vectors to improve the immune response to antigens
04/24/2003WO2003033016A1 Use of neurotrophic factors for treating neurodegenerative diseases and cancer
04/24/2003WO2003033013A1 Use of aplidine for the treatment of pancreatic cancer
04/24/2003WO2003033012A1 Kahalalide compounds for use in cancer therapy
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033006A1 Extract of ceratonia siliqua leaves and pods containing polyphenols with antioxidant and antitumor activities
04/24/2003WO2003032999A1 Alkyne matrix metalloproteinase inhibitors
04/24/2003WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
04/24/2003WO2003032993A1 Use of phosphorodiesterase iv inhibitors
04/24/2003WO2003032988A1 Pharmaceutical composition
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032984A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
04/24/2003WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032979A1 Malignant cell differentiation inducer compositions and utilization of the same
04/24/2003WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003WO2003032955A1 Highly compressible ethylcellulose for tableting
04/24/2003WO2003032950A1 Pharmaceutical formulation comprising (r) -bicalutamide
04/24/2003WO2003032921A2 Treatment of neurodegenerative diseases and cancer of the brain
04/24/2003WO2003032920A2 Oligonucleotide modulation of cell adhesion
04/24/2003WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003WO2003032911A2 Anti-angiogenic and cytotoxic fused pyrimidines
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032907A2 High-concentration protein formulations and method of manufacture
04/24/2003WO2003032906A2 Delivery of poorly soluble drugs
04/24/2003WO2003032905A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity
04/24/2003WO2003032903A2 Trisubstituted triazines compounds with antitubulin activity
04/24/2003WO2003032902A2 Tumor targeted photodiagnostic-phototherapeutic agents
04/24/2003WO2003032901A2 Pathological tissue detection and treatment employing targeted benzoindole optical agents
04/24/2003WO2003032900A2 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications